Walking the tightrope in prevention of mother-to-child transmission of HIV infection

Clinical Infectious Diseases

Volumn 46, Issue 4, 2008, Pages 622-624

  Gray, Glenda E ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZALCITABINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL THERAPY; CD4+ T LYMPHOCYTE; CONFIDENCE INTERVAL; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INTRAPARTUM CARE; LYMPHOCYTE COUNT; MOTHER CHILD RELATION; NOTE; PREDICTION; PRIORITY JOURNAL; PUERPERIUM; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS TRANSMISSION; ADULT; ANTIVIRAL RESISTANCE; DISEASE TRANSMISSION; FEMALE; HUMAN; PREGNANCY;

ADULT; ANTI-HIV AGENTS; DISEASE TRANSMISSION, VERTICAL; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HUMANS; PREGNANCY;

EID: 38849186171     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/526781     Document Type: Note

References (14)

1. Arrive E, Newell ML, Ekouevi DK, et al.; the Ghent Group on HIV in Women and Children. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol 2007; 36:1009-21.
2. Chaix ML, Ekouevi DK, Peytavin G, et al. Impact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected children. Antimicrob Agents Chemother 2007; 51:896-901.
3. Chaix ML, Ekouevi DK, Rouet F, et al.; Agence Nationale de Recherches sur le SIDA Ditrame Plus Study Group. Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire. J Infect Dis 2006; 193:482-7.
4. Eshleman SH, Church JD, Chen S, et al. Comparison of HIV-1 mother-to-child transmission after single-dose nevirapine prophylaxis among African women with subtypes A, C, and D. J Acquir Immune Defic Syndr 2006; 42:518-21.
5. Eshleman SH, Jackson JB. Nevirapine resistance after single dose prophylaxis. AIDS Rev 2002; 4:59-63.
6. Martinson N, Morris L, Gray G, et al. HIV resistance and transmission following single-dose nevirapine in a PMTCT cohort [abstract 38]. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections (San Francisco). Alexandria, VA: Foundation for Retrovirology and Human Health, 2004.
7. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007; 356:135-47.
8. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al.; Perinatal HIV Prevention Trial Group. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 2004; 351:229-40.
9. McIntyre J, Martinson N, Boltz V. Single dose nevirapine combined with short course combivir for prevention of mother-to-child transmission of HIV-1 can significantly decrease the subsequent development of maternal and infant resistant virus [abstract TuFo2004]. In: Program and abstracts of the 3rd International AIDS Society Conference (Rio de Janeiro). Stockholm: International AIDS Society, 2005.
10. Coffie PA, Ekouevi DK, Chaix M-L, et al. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Côte d'Ivorie, 2003-2006. Clin Infect Dis 2008; 46:611-21 (in this issue).
11. Rezende LF, Drosopoulos WC, Prasad VR. The influence of 3TC resistance mutation M184I on the fidelity and error specificity of human immunodeficiency virus type 1 reverse transcriptase. Nucleic Acids Res 1998; 26:3066-72.
12. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 2006; 296:679-90.
13. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 2007; 4:e298.
14. Braitstein P, Brinkhof MW, Dabis F, et al.; Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration, ART Cohort Collaboration (ART-CC) groups. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367:817-24 (erratum: 2006; 367:1902).